Research
Emerging strategies and clinical recommendations for the management of novel depression subtypes.
Expert review of neurotherapeutics – April 01, 2025
Summary
Depression manifests differently today due to modern pressures and social changes. New research reveals distinct subtypes, including early-onset depression in youth, cases linked to social disconnection, and those complicated by substance use disorders. Treatment success comes from matching approaches to specific needs - combining traditional antidepressants with targeted interventions like specialized therapy and newer options such as ketamine for resistant cases.
Abstract
The phenomenology of depression is characterized by a wide array of emotional, cognitive, and physical symptoms that significantly disrupt an indiv...
Did Serendipity Contribute to the Discovery of New Antidepressant Drugs? Historical Analysis Using Operational Criteria.
Alpha psychiatry – April 01, 2025
Summary
Contrary to popular belief, most modern antidepressants weren't discovered by accident. A comprehensive analysis of psychopharmacology history reveals that while chance discoveries shaped early treatments, contemporary antidepressants largely stem from intentional research. Only two notable exceptions exist: moclobemide, originally studied for cholesterol control, and ketamine, whose mood-lifting properties were noticed in recreational users.
Abstract
Given their great importance, as one of the most prescribed types of therapeutic drugs worldwide, we have analyzed the role of serendipity in the d...
Exploring the impact of MDMA and oxytocin ligands on anxiety and social responses: A comprehensive behavioural and molecular study in the zebrafish model.
Journal of psychopharmacology (Oxford, England) – April 01, 2025
Summary
MDMA, known for boosting social connection, shows promise in treating anxiety disorders through its interaction with the brain's oxytocin system. In zebrafish tests, low doses of MDMA reduced anxiety behavior and increased social interaction. The drug worked by adjusting key brain chemicals and hormones, particularly boosting oxytocin receptor activity while decreasing stress responses. These findings reveal how MDMA's unique effects could help people with social and anxiety challenges.
Abstract
Mental disorders, including anxiety and depression, impact nearly 1 billion people worldwide. Recent research has highlighted the potential of cert...
Volumetric mesoscopic electrophysiology: a new imaging modality for the nonhuman primate.
Journal of neurophysiology – April 01, 2025
Summary
Scientists have developed a groundbreaking way to observe brain activity across an entire primate hemisphere simultaneously. By implanting nearly 1,000 sensors throughout the brain, researchers captured detailed electrical signals (local field potentials) with unprecedented coverage. The technique revealed how ketamine, a drug that can mirror schizophrenia-like states, disrupts normal brain connectivity patterns during resting state. This advancement bridges the gap between traditional EEG and other brain imaging methods, offering both wide coverage and precise timing.
Abstract
The primate brain is a densely interconnected organ whose function is best understood by recording from the entire structure in parallel, rather th...
Ketamine: An emerging agent in the management of neuropsychiatric disorders.
Asian journal of psychiatry – April 01, 2025
Summary
Once used solely as an anesthetic, ketamine has emerged as a groundbreaking treatment for multiple mental health conditions. This rapid-acting medication shows promise in treating substance use disorders, including alcohol and cocaine dependence. It's particularly effective for managing both acute and chronic pain, while also helping ease the difficult symptoms of opioid and alcohol withdrawal. Recent evidence suggests ketamine can quickly calm severe agitation and reduce drug cravings, offering new hope for addiction treatment.
Abstract
Ketamine's unique pharmacological profile, safety, modulation of multiple neurotransmitter systems, and ability to produce neuroplastic changes mak...
Inhibition of autophagy by esketamine attenuates hypoxia/reoxygenation injury in cardiomyocytes via inhibition of Ca2+/CaMKKβ/AMPK/mTOR pathway by down-regulation of transient receptor potential vanilloid 1 expression.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society – April 01, 2025
Summary
Heart cells under stress can repair themselves through a process called autophagy, but sometimes this self-repair goes wrong. New research shows esketamine, a medication known for treating depression, may protect heart cells during oxygen deprivation by regulating calcium levels and cell repair mechanisms. This finding suggests esketamine could help prevent heart damage during cardiac events by fine-tuning the body's natural repair systems.
Abstract
This research sought to determine the influence of esketamine (ESK) on hypoxia/reoxygenation (H/R) injury in cardiomyocytes by blocking autophagy v...
Increased sensitivity to psychomotor effects of ketamine enantiomers in the Wistar-Kyoto depression model.
Journal of psychiatric research – April 01, 2025
Summary
Groundbreaking research reveals that depressed subjects may be more sensitive to ketamine's effects than previously thought. Scientists compared two forms (enantiomers) of this promising antidepressant in a depression model using specialized Wistar-Kyoto rats. The S-form showed stronger immediate psychomotor effects than its R-counterpart, particularly in depressed subjects. However, with repeated treatment, tolerance developed, suggesting side effects may decrease over time.
Abstract
Ketamine, a fast-acting antidepressant, is a racemic mixture, composed of equal amounts of R- and S-ketamine. Preclinical studies are comparing the...
Ayahuasca and debut of psychosis, description of a clinical case
European Psychiatry – April 01, 2025
Summary
Ayahuasca, a powerful hallucinogenic brew, can trigger psychotic episodes in individuals with a history of psychiatric disorders. A case involving a patient who required hospitalization after consuming ayahuasca illustrates this risk. Treatment with antipsychotics led to complete symptom resolution. Given the increasing popularity of ayahuasca, understanding its effects is crucial; hallucinogens can exacerbate psychotic symptoms and may interact negatively with psychiatric medications. Awareness and psychoeducation are essential to mitigate these risks while exploring potential therapeutic benefits.
Abstract
Introduction The relationship between psychosis and ayahuasca use is a topic of considerable interest and debate in the scientific and medical comm...
Mindful young brains and minds: a systematic review of the neural correlates of mindfulness-based interventions in youth.
Brain imaging and behavior – April 01, 2025
Summary
No Summary
Abstract
This systematic narrative review examines neuroimaging studies that investigated the neural correlates of mindfulness-based interventions in youth ...
[Application and Promotion of Mindfulness and Compassion in Healthcare].
Hu li za zhi The journal of nursing – April 01, 2025
Summary
No Summary
Abstract
Mindfulness and compassion have gained increasing recognition in global healthcare and nursing fields in recent years as important strategies for e...
To Move or Not to Move: Factors of Mind-Body Practice Engagement in a Population-Based Study.
Journal of integrative and complementary medicine – April 01, 2025
Summary
No Summary
Abstract
Background: Mind-body practices (MBPs), which include seated- (meditation) and movement-based practices (yoga, Tai Chi, qigong), have grown increas...
Decoding Mindfulness With Multivariate Predictive Models.
Biological psychiatry. Cognitive neuroscience and neuroimaging – April 01, 2025
Summary
No Summary
Abstract
Identifying the brain mechanisms that underlie the salutary effects of mindfulness meditation and related practices is a critical goal of contempla...
ENIGMA-Meditation: Worldwide Consortium for Neuroscientific Investigations of Meditation Practices.
Biological psychiatry. Cognitive neuroscience and neuroimaging – April 01, 2025
Summary
No Summary
Abstract
Meditation is a family of ancient and contemporary contemplative mind-body practices that can modulate psychological processes, awareness, and ment...
Regulation of Stress Physiology While Parenting: a Randomized Micro-trial of Loving-Kindness Meditation on Parenting and Salivary Alpha Amylase.
Prevention science : the official journal of the Society for Prevention Research – April 01, 2025
Summary
No Summary
Abstract
Sensitive parenting early in life sets children up for healthy development, and this type of parenting draws on the parent's compassion and physiol...
Closed-Loop Systems and Real-Time Neurofeedback in Mindfulness Meditation Research.
Biological psychiatry. Cognitive neuroscience and neuroimaging – April 01, 2025
Summary
No Summary
Abstract
Mindfulness meditation has numerous purported benefits for psychological well-being; however, problems such as adherence to mindfulness tasks, qual...
Analytical and behavioral characterization of 1-hexanoyl-LSD (1H-LSD).
Drug testing and analysis – April 01, 2025
Summary
A new LSD-related compound shows promise in lab studies, demonstrating similar potency to existing psychedelics. Scientists found that 1H-LSD triggers the same head-twitch response in mice as traditional LSD, suggesting comparable psychoactive effects. This new psychoactive substance likely converts to LSD in the body, acting as a delivery mechanism that could inform future therapeutic applications.
Abstract
The development of lysergic acid diethylamide (LSD) derivatives and analogs continues to inform the design of novel receptor probes and potentially...
Tripping on Mushrooms with Edward Said: The Case for Literary Studies as Holistic Medicine
South Atlantic Quarterly – April 01, 2025
Summary
Benefits of psychedelics like LSD and psilocybin arise from how individuals interpret their intense experiences, or "tripping." Crucial to drug studies, this suggests transformative potential for self-perception and anxiety reduction lies in cultural understanding. These aesthetically rich, extraordinary sensory states offer a framework for critical thought. Drawing on spiritual practices' history, this perspective cultivates skills to reframe global catastrophes—from climate change to mental health crises—opening new dimensions for art and creativity.
Abstract
This piece introduces the special issue of SAQ “Psychedelic Imaginaries,” which collates fresh and theoretically sophisticated humanist perspective...
Hepatic adverse events associated with ketamine and esketamine: A population-based disproportionality analysis.
Journal of affective disorders – April 01, 2025
Summary
Recent data reveals surprising liver safety differences between ketamine and esketamine, two promising treatments for depression. Analysis of FDA adverse event reports shows ketamine has lower rates of serious liver problems compared to common pain relievers, though some mild liver function changes were noted. Esketamine showed minimal liver concerns overall, except for rare cases of liver failure. Regular liver testing is recommended for long-term users.
Abstract
To determine whether there is disproportionate reporting of hepatobiliary disorders in the United States (US) FDA Adverse Event Reporting System (F...
Predictors of Recovering Full Consciousness: Results From a Prospective Multisite Italian Study.
European journal of neurology – April 01, 2025
Summary
Visual responsiveness and brain activity patterns can predict recovery in patients with severe brain injuries, according to groundbreaking research from Italian rehabilitation centers. Following 131 patients with disorders of consciousness, specialists found that those with better visual responses and specific neurophysiology markers had higher chances of regaining full consciousness within 3 months of intensive rehabilitation. This insight helps doctors provide more accurate recovery forecasts.
Abstract
Improving prognostication in patients with a prolonged disorder of consciousness (pDoC) is among the most challenging issues in neurorehabilitation...
Mitigating Ethical Issues in Training for Psychedelic Therapy
Neuroethics – April 01, 2025
Summary
Protecting vulnerable individuals in psychedelic therapy demands rigorous ethical training, echoing principles from medical education and engineering ethics. Four critical problems are identified: insufficient comprehensive psychology-informed training, a lack of psychotherapist experience, inappropriate self-disclosure, and "guruism." Mitigating these requires robust ethics codes, monitoring, and professional licensure for those in psychedelics and drug studies. Practitioners need specific training, and a cooling-off period after personal psychedelic experiences is vital for responsible practice in this neuropsychology-adjacent field.
Abstract
Abstract In the present paper, we analyze the ethical issues in training for psychedelic therapy and discuss mitigation strategies for these issues...
Prediction of hallucinogen persisting perception disorder and thought disturbance symptoms following psychedelic use.
PNAS nexus – April 01, 2025
Summary
Psychedelics may actually reduce delusional thinking patterns, according to recent findings. While 30% of users reported minor visual disturbances (HPPD-like effects), less than 1% found these changes distressing. Young women and those with prior psychiatric diagnoses were more likely to experience these adverse effects. Notably, psychedelic use was linked to decreased delusional ideation, challenging concerns about magical thinking.
Abstract
Interest in using psychedelic drugs to treat psychiatric disorders is growing rapidly. While modern controlled clinical trials show a favorable saf...
Mindfulness Meditation and Network Neuroscience: Review, Synthesis, and Future Directions.
Biological psychiatry. Cognitive neuroscience and neuroimaging – April 01, 2025
Summary
No Summary
Abstract
Network neuroscience is an interdisciplinary field, which can be used to understand the brain by examining the connections between its constituent ...
Characterization of the temporal profile of the antinociceptive effects of an intravenous bolus of ketamine using the analgesia nociception index in no-anesthetized adult patients.
Journal of clinical monitoring and computing – April 01, 2025
Summary
Ketamine's pain-relieving effects peak just 2 minutes after injection, offering rapid relief for patients. This groundbreaking pharmacology research tracked how ketamine influences pain perception by monitoring the body's analgesia-nociception balance in 20 awake patients. Results showed ketamine significantly improved pain control scores from 38 to 53, demonstrating its effectiveness as a fast-acting analgesic medication.
Abstract
An effect-site target-controlled infusion (TCI) would allow a more precise titration of intravenous analgesics effect. The analgesia nociception in...
Midazolam and Ketamine for Convulsive Status Epilepticus in the Out-of-Hospital Setting.
Annals of emergency medicine – April 01, 2025
Summary
When treating severe seizures outside hospitals, combining ketamine with midazolam stops convulsions in 94% of cases - significantly better than using midazolam alone. This breakthrough finding comes from analyzing hundreds of emergency responses in Florida, where adding ketamine helped an additional 14% of patients recover before reaching the hospital, offering new hope for rapid seizure control.
Abstract
To determine if ketamine, when added to midazolam for the treatment of out-of-hospital seizures, is associated with an increase in the rate of cess...
Large-scale brain connectivity changes following the administration of lysergic acid diethylamide, d-amphetamine, and 3,4-methylenedioxyamphetamine.
Molecular psychiatry – April 01, 2025
Summary
Psychedelics and stimulants reshape brain networks differently, with LSD showing unique effects on the brain's "default mode" - regions active when we're lost in thought. This research tracked brain connectivity changes in 28 healthy volunteers after taking LSD, MDMA, or amphetamine. While all substances altered brain network communication, LSD stood out by increasing connectivity between the brain's command centers while reducing it in visual areas. MDMA and amphetamine showed overlapping but distinct patterns, suggesting each substance uniquely influences how brain regions talk to each other.
Abstract
Psychedelics have recently attracted significant attention for their potential to mitigate symptoms associated with various psychiatric disorders. ...
Ayahuasca enhances the formation of hippocampal-dependent episodic memory without impacting false memory susceptibility in experienced ayahuasca users: An observational study.
Journal of psychopharmacology (Oxford, England) – April 01, 2025
Summary
Regular ayahuasca users showed improved memory formation without increased risk of false memories, contrary to expectations about psychedelics. Experienced members of the Santo Daime church demonstrated enhanced episodic memory and recollection after consuming their ceremonial brew, while maintaining accurate recall and familiar memory processing. This suggests ayahuasca may uniquely benefit memory formation.
Abstract
Ayahuasca is an Amazonian brew with 5-HT2A-dependent psychedelic effects taken by religious groups globally. Recently, psychedelics have been shown...
Connectome harmonic decomposition tracks the presence of disconnected consciousness during ketamine-induced unresponsiveness.
British journal of anaesthesia – April 01, 2025
Summary
During ketamine-induced sedation, people often experience vivid dreams despite being unresponsive. Scientists used advanced brain imaging to reveal that ketamine creates unique brain wave patterns similar to psychedelic states, but different from unconscious states caused by other anesthetics or injury. This suggests consciousness can persist even when people can't respond.
Abstract
Ketamine, in doses suitable to induce anaesthesia in humans, gives rise to a unique state of unresponsiveness accompanied by vivid experiences and ...
The effect of Psilocybe cubensis alkaloids on depressive-like behavior in mice exposed to maternal separation with respect to hippocampal gene expression and DNA methylation of Slc6a4 and Nr3c1.
Behavioural pharmacology – April 01, 2025
Summary
Magic mushroom compounds show promise in treating depression linked to early childhood stress. Researchers found that extracts from Psilocybe mushrooms reversed depression-like behaviors in mice separated from their mothers as infants. The treatment worked by changing gene activity in the brain's memory center, boosting serotonin signaling and improving stress responses. The effects lasted up to 10 days after a single dose.
Abstract
Maternal separation as an early life stress can lead to long-lasting deleterious effects on cognitive and behavioral functions, and the mood state....
[Interventional psychiatric procedures and novel substances for the treatment of affective disorders: An overview and outlook].
Therapeutische Umschau. Revue therapeutique – April 01, 2025
Summary
Breakthrough treatments are transforming care for treatment-resistant depression. Modern interventions like ketamine therapy and rTMS offer hope for the 33% of patients who don't respond to traditional antidepressants. From gentle tDCS to targeted DBS, doctors now have multiple tools to help patients achieve remission. ECT remains highly effective, while emerging options like psychedelic-assisted therapy show promise for personalized mental health care.
Abstract
Depression is one of the most common mental disorders. The effectiveness of pharmacological and psychotherapeutic treatments is well documented. Re...
Ketamine-Assisted Psychotherapy for Treatment of Co-occurring Borderline Personality Disorder and Depression: A Case Study.
Journal of personality disorders – April 01, 2025
Summary
A groundbreaking treatment combining ketamine with psychotherapy showed remarkable success in helping a patient overcome both borderline personality disorder and severe depression. The patient experienced significant improvement in mood stability and interpersonal relationships after receiving ketamine-assisted psychotherapy sessions. This innovative approach leverages ketamine's unique properties to enhance emotional processing while providing structured therapeutic support, leading to reduced symptoms and improved daily functioning. The treatment proved particularly effective in addressing the complex challenges of co-occurring mental health conditions.
Abstract
Borderline personality disorder (BPD) is a mental health condition characterized by a pervasive pattern of impulsivity, affective dysregulation, an...
Determination of 5-OH-DMT (bufotenine) in the Asian toad Duttyphrynus melanostictus, Hoplobatrachus tigerinus and Haemopis sanguisiga in Madagascar by UHPLC-MS/MS.
Environmental toxicology and pharmacology – April 01, 2025
Summary
Fascinating discovery in Madagascar: Asian toads carry varying levels of bufotenine, a natural psychoactive compound, throughout their lifecycle. Scientists found this substance in local toads, frogs, and leeches using advanced chemical analysis. The compound increases as tadpoles develop into adult toads, though interestingly, it's absent in toad eggs. This reveals how toxins move through Madagascar's food chain.
Abstract
5-hydroxy-N,N-dimethyltryptamine (5-OH-DMT), known as bufotenine, is proven to have psychoactive effects in high concentrations. Duttyphrynus melan...
A reflection on paradigmatic tensions within the FDA advisory committee for MDMA-assisted therapy.
Journal of psychopharmacology (Oxford, England) – April 01, 2025
Summary
A pivotal moment in modern psychiatry unfolds as psychedelics challenge traditional drug approval frameworks. The FDA's approach to MDMA therapy highlights a fundamental clash between conventional psychopharmacology, which views drugs as purely biological agents, and an emerging paradigm that recognizes the vital role of set and setting in treatment outcomes. This tension reflects a broader shift in how we understand mental health interventions, particularly when psychedelics are combined with therapy.
Abstract
The recent rejection of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy by the U.S. Food and Drug Administration (FDA) is a dramatic mome...
Enhancing Equanimity With Noninvasive Brain Stimulation: A Novel Framework for Mindfulness Interventions.
Biological psychiatry. Cognitive neuroscience and neuroimaging – April 01, 2025
Summary
No Summary
Abstract
Mindfulness has gained widespread recognition for its benefits for mental health, cognitive performance, and well-being. However, the multifaceted ...
Psilocybin Dispensaries and Online Health Claims in Canada
JAMA Network Open – April 01, 2025
Summary
Over a third of major Canadian cities contain unregulated psilocybin dispensaries, with 2.6% of Canadians living near one. A recent analysis identified 57 such businesses, many operating online and as chains. While 86.4% of websites advertise psilocybin products with mental health claims, only 9.1% warn against driving, and specific warnings for pregnancy or psychosis are also rare. This lack of clear guidance from the business sector, despite diverse product offerings, poses significant public health risks in the realm of psychedelics and medicine.
Abstract
Importance There is growing societal interest in and use of psilocybin. While psilocybin in Canada is illegal outside of clinical trials, there hav...
Using Electroencephalography to Advance Mindfulness Science: A Survey of Emerging Methods and Approaches.
Biological psychiatry. Cognitive neuroscience and neuroimaging – April 01, 2025
Summary
No Summary
Abstract
Throughout the brief history of contemplative neuroscience, electroencephalography (EEG) has been a valuable and enduring methodology used to eluci...
The Use of Prophylactic Ketamine to Mitigate Postoperative Depressive Symptoms: A Systematic Review.
Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses – April 01, 2025
Summary
A single dose of ketamine during surgery could significantly reduce post-surgical depression, offering hope for millions. This comprehensive analysis of nine clinical trials found that administering ketamine during operations helped prevent depressive symptoms in most surgical patients. When given during or immediately after surgery, ketamine not only aided recovery but also protected mental well-being, with minimal surgical complications. Seven out of nine studies showed marked improvement in mood scores, suggesting this approach could transform how hospitals address post-surgical depression.
Abstract
Depression is predicted to be the leading burden of disease worldwide by 2030 with a prevalence of 10% to 60% in the surgical population. Depressiv...
Dream habits in a large cohort of preteens and their relation to sleep and nocturnal awakenings.
Journal of sleep research – April 01, 2025
Summary
No Summary
Abstract
The present study examined dream habits, and their relation to sleep patterns, in 1151 preteens (597 boys; 554 girls; 11.31 ± 0.62 years old). Drea...
The Lethal Combination of Pregabalin With Other Recreational Drugs.
Cureus – April 01, 2025
Summary
Mixing Lyrica (pregabalin) with recreational drugs can have devastating effects on mental and physical health. A troubling case revealed how combining ketamine with pregabalin led to severe delusions, confusion, and toxic encephalopathy in a young adult. The patient's drug abuse resulted in kidney damage and required intensive medical care. Recovery was achieved through careful treatment of both physical symptoms and underlying substance use issues.
Abstract
This case presents a 33-year-old male with a four-day history of worsening altered mental status and rhabdomyolysis. He experienced delusions, rest...
Comparative Efficacy and Functional Outcomes of Psychedelic-Assisted Therapies in Treatment-Resistant Depression: A Systematic Review of Recent Clinical Trials.
Cureus – April 01, 2025
Summary
Breakthrough findings show 70% of patients with hard-to-treat depression improved significantly with psychedelic-assisted therapy. Analysis of recent trials reveals both ketamine and psilocybin treatments led to rapid antidepressant response, with benefits lasting months. Depression scales showed marked improvement in mood, while cognitive effects remained stable or enhanced. This comprehensive review confirms these treatments are safe and effective for treatment-resistant depression.
Abstract
This systematic review explores the comparative efficacy and functional outcomes of psychedelic-assisted therapies in the management of treatment-r...
Psychedelics and connectedness to natural and social worlds: An examination of the evidence and a proposed conceptual framework.
Current opinion in psychology – April 01, 2025
Summary
No Summary
Abstract
Recent research suggests that serotonergic psychedelics may simultaneously enhance connectedness to both social and natural worlds. This article sy...
Reconsidering evidence for psychedelic-induced psychosis: An overview of reviews, a systematic review, and meta-analysis of human studies
European Psychiatry – April 01, 2025
Summary
Psychedelics and Drug Studies reveal a remarkably low 0.002% incidence of psychedelic-induced psychosis in the general population (N=123,800). However, among individuals with schizophrenia, 3.8% (N=133) experienced long-lasting psychotic symptoms after psychedelic exposure. Furthermore, 13.1% (N=353) of those who experienced psychedelic-induced psychosis later developed schizophrenia. While the overall risk is low, these findings suggest a higher risk for individuals with pre-existing conditions, indicating careful consideration for future clinical trials exploring these substances.
Abstract
Introduction Persons with schizophrenia are currently excluded from psychedelic-assisted therapy due to concerns about psychedelic-induced acute or...
Ketamine Versus Electroconvulsive Therapy for the Treatment of Depression: A Guide for Clinicians.
Focus (American Psychiatric Publishing) – April 01, 2025
Summary
When traditional antidepressants fail, two powerful options emerge: ketamine and electroconvulsive therapy. Both treatments show remarkable success for treatment-resistant depression, with distinct advantages. Ketamine offers rapid relief with fewer side effects, while electroconvulsive therapy remains highly effective for severe major depressive disorder. Patient-centered factors like medical history and lifestyle help determine the best choice.
Abstract
The effective treatment of major depressive disorder remains one of the biggest public health challenges globally. For moderate to severe cases, ph...
Comparison of the analgesic dose of intravenous ketamine versus ketorolac in patients with chest trauma: A randomized double-blind clinical trial.
Academic emergency medicine : official journal of the Society for Academic Emergency Medicine – April 01, 2025
Summary
For patients with chest injuries, effective pain control can speed healing and improve outcomes. New research shows ketamine outperforms traditional ketorolac for managing severe chest pain, including in patients with rib fractures. In a 90-patient trial, those receiving ketamine reported significantly lower pain scores after 30 and 60 minutes, and needed less additional pain medication. While ketamine caused more nausea, it proved especially effective for patients with chest tubes.
Abstract
Pain management is a critical part of treatment in patients with chest trauma. Opioids and nonsteroidal anti-inflammatory drugs have been the most ...
Posterior Reversible Encephalopathy Syndrome in the Postpartum Period: A Rare Entity With Atypical Presentation.
Cureus – April 01, 2025
Summary
A rare but reversible brain condition can strike new mothers even without typical pregnancy complications like high blood pressure. This neurologic disorder causes temporary vision loss and memory problems due to brain swelling. Advanced imaging revealed unusual swelling patterns in the patient's brain, helping doctors diagnose and successfully treat this postpartum condition through prompt medical intervention.
Abstract
Posterior reversible encephalopathy syndrome (PRES) is a rare condition characterized by clinical and brain imaging criteria. It is most often asso...
De Novo Biosynthesis of Antidepressant Psilocybin in Escherichia coli
Microbial Biotechnology – April 01, 2025
Summary
Psilocybin, a tryptamine-derived alkaloid, holds Breakthrough Therapy status for depression, addressing Tryptophan and brain disorders. Its sustainable production is crucial for Psychedelics and Drug Studies. Scientists engineered *Escherichia coli* to overcome low *Enzyme* activity in its *Biosynthesis*. Through clever Biochemistry and Chemistry, including N-terminal modifications and precursor supply, they boosted norbaeocystin production 33-fold to 105.3 mg/L. Ultimately, this improved *Biology* yielded 79.4 mg/L of psilocybin, a 100-fold increase, advancing efficient chemical synthesis of this important compound.
Abstract
ABSTRACT Psilocybin, a tryptamine‐derived alkaloid, has been granted Breakthrough Therapy designation by the U.S. FDA for treatment‐resistant depre...
Development and Initial Validation of the State Four Facet Mindfulness Questionnaire.
Assessment – March 31, 2025
Summary
No Summary
Abstract
The current research aimed to provide initial psychometric validation of a new multifaceted mindfulness questionnaire (referred to as the State Fou...
Utilizing Psychedelics to Enhance Well-Being: A Systematic Review
Journal of Psychoactive Drugs – March 31, 2025
Summary
Psychedelics significantly enhance well-being in healthy individuals, moving beyond their therapeutic use for illness. An analysis of 19 studies, encompassing 949 participants, revealed enduring improvements across well-being's five elements. Substances like psilocybin, lysergic acid diethylamide, and ayahuasca consistently fostered positive emotions, engagement, and meaning. This suggests a paradigm shift in psychology and psychiatry, recognizing how these hallucinogens support human flourishing. Psychotherapists could explore these compounds, which are products of chemical synthesis and natural alkaloids, for their profound influence on behavior, promoting holistic well-being.
Abstract
Psychedelic-assisted therapy is gaining recognition for its potential to enhance human functioning. While most research has focused on psychedelic'...
Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms.
Psychol Med – March 31, 2025
Summary
Contrary to common concerns, people who use psychedelics like psilocybin and LSD don't show increased risk of psychotic or manic symptoms over time. Data from 2,700+ participants tracked over several months revealed that psychedelic use was actually linked to fewer psychotic-like experiences and manic symptoms compared to non-users, challenging previous assumptions about these substances' mental health risks.
Abstract
Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms.
The Afterglow Inventory (AGI): Validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics
Journal of Psychopharmacology – March 31, 2025
Summary
The positive psychological "Afterglow" from hallucinogens like psilocybin or lysergic acid diethylamide is now quantifiable. A 24-item Afterglow Inventory (AGI) was developed from 97 initial items, surveying 1323 psychedelic users and 157 controls. The AGI effectively distinguishes groups, crucial for clinical psychology and Psychedelics and Drug Studies. AGI scores correlated with acute effect intensity (r=0.165) and positive valence (r=0.251), revealing how these chemical synthesis and alkaloids influence behavior via neurotransmitter receptors.
Abstract
Background: Classic psychedelics such as psilocybin and lysergic acid diethylamide are anecdotally associated with the phenomenon of “psychedelic a...
Effects of a single dose of psilocybin on diet-induced weight loss in obese mice
OpenAlex – March 31, 2025
Summary
Psilocybin, a hallucinogen, significantly enhanced weight loss in diet-induced obese mice. A single dose of this psychedelic compound exacerbated weight loss over four weeks in animal subjects adopting a low-fat diet. This pharmacology intervention primarily modulated food intake, influencing behavior, but showed no effect on energy expenditure. No weight loss occurred when mice remained on a high-fat diet. This suggests psilocybin facilitates weight loss for obesity only with other interventions, offering new insights into endocrinology and neural plasticity via biochemical mechanisms.
Abstract
Abstract Prolonged obesity induces enduring structural changes within neural circuits that contribute to maintaining the body at an elevated/obese ...
Premorbid characteristics of the SAPAP3 mouse model of obsessive-compulsive disorder: behavior, neuroplasticity, and psilocybin treatment
The International Journal of Neuropsychopharmacology – March 29, 2025
Summary
Juvenile mice modeling Obsessive-Compulsive Spectrum Disorders display significant anxiety *before* grooming behaviors, informing Psychology. Using open field and elevated plus maze tests, these juvenile animals showed anxiety. Psilocybin (4.4 mg/kg) did not alleviate this, a key insight for Psychedelics and Drug Studies and Neurotransmitter Receptor Influence on Behavior. Neuroscience reveals that while adult mice exhibited increased Synaptophysin and Gap-43 protein in the Hippocampus and Amygdala, reflecting synaptic plasticity and neuroplasticity, juvenile brains did not. SAPAP3 is a postsynaptic density scaffold protein, suggesting age-dependent adaptations.
Abstract
Abstract Background SAPAP3-knockout (SAPAP3-KO) mice develop excessive self-grooming behavior at 4-6 months of age, serving as a model for obsessiv...
Assessing willingness and preference for body scan practices in ADHD: a survey study.
BMC complementary medicine and therapies – March 29, 2025
Summary
No Summary
Abstract
Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental condition, but current treatment options are limited. Although medic...
Clinical Research on Lysergic Acid Diethylamide (LSD) in Psychiatry and Neuroscience.
Pharmaceuticals (Basel, Switzerland) – March 29, 2025
Summary
Recent clinical research shows LSD works by activating specific serotonin receptors in the brain, producing profound effects on mood and consciousness. When combined with therapy, this psychedelic medicine significantly reduced anxiety and depression in 79% of participants. Studies reveal that a single supervised session can create lasting positive changes in mental health and addiction recovery.
Abstract
Lysergic acid diethylamide (LSD) is gaining renewed interest as a potential treatment for anxiety, depression, and alcohol use disorder, with clini...
Prophylactic Ketamine: Current Knowledge and Future Directions.
Biological psychiatry – March 28, 2025
Summary
Recent findings suggest ketamine, traditionally used as an anesthetic, shows remarkable potential as a neuroprotective drug when given before stressful events. This prophylactic treatment appears to build stress resilience, potentially preventing stress-induced psychiatric disorders before they develop. Studies demonstrate that low doses administered preventively can strengthen neural pathways, reduce inflammation, and enhance the brain's natural protective mechanisms.
Abstract
The prevalence of stress-induced disorders, including depression, anxiety, posttraumatic stress disorder, and postpartum depression, has been incre...
Repeated administration of a subanesthetic dose of ketamine results in impaired motor and cognitive behavior and differential expression of hippocampal P2X1 and P2X7 receptors in adult mice.
Behavioural brain research – March 28, 2025
Summary
Ketamine's effects on the brain vary dramatically with age, revealing surprising differences in how young and adult mice respond to repeated exposure. Adult mice showed significant impairment in nest-building behavior and memory tasks, while younger mice remained largely unaffected. The hippocampus, crucial for memory, displayed opposite patterns in protein expression between age groups, with adult mice showing increased P2X1 and decreased P2X7 levels - potentially explaining their greater vulnerability to ketamine's effects.
Abstract
Ketamine hydrochloride serves multiple purposes, including its use as a general anesthetic, treatment for depression, and recreational drug. In stu...
Tags
How to set up a psychedelic study: Unique considerations for research involving human participants
arXiv Preprint Archive – March 28, 2025
Summary
Establishing psychedelic research trials is uniquely complex, challenging existing medical assumptions. Leading UK teams have distilled their collective experience into a practical guide. This resource formalizes essential considerations, simplifying the arduous setup process for future studies. It offers clear recommendations for researchers and policymakers, streamlining the path for groundbreaking work in q-bio.NC and advancing our understanding of these powerful compounds.
Abstract
Setting up a psychedelic study can be a long, arduous, and kafkaesque process. This rapidly-developing field poses several unique challenges for re...
Effectiveness of heartfulness meditation in the management of recurrent aphthous ulcers.
Dental and medical problems – March 28, 2025
Summary
No Summary
Abstract
Recurrent aphthous ulcers (RAUs) are the most prevalent form of painful oral mucosal disorder. Conventional treatment for RAUs involves the adminis...
Evaluation of curricular mindfulness micro-interventions to support college student resilience: a pilot study.
Journal of American college health : J of ACH – March 28, 2025
Summary
No Summary
Abstract
Objective: This study addressed two research questions: (1) What is the feasibility of embedding curricular resilience micro-interventions across c...
Pendulums in medical practice.
The Medico-legal journal – March 27, 2025
Summary
No Summary
Abstract
Medicine is taught as a science, but in reality, as with other areas that undergo much public scrutiny, it is often more of an art than a science. ...
Neurophysin I: a reliable, novel, and robust biomarker for oxytocin.
European journal of endocrinology – March 27, 2025
Summary
A breakthrough in measuring the "love hormone" oxytocin reveals Neurophysin I as a reliable biomarker. Using MDMA as a stimulation test, researchers found that healthy people showed a 20-fold increase in this biomarker, while those with posterior pituitary dysfunction showed minimal response. This discovery offers a new diagnostic tool for oxytocin deficiency and could improve treatment for social and emotional disorders.
Abstract
Oxytocin (OXT) deficiency is a recently identified novel psycho-neuroendocrine entity associated with anxiety and reduced prosocial behavior. Howev...